Mohammad Azab

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Jean‐Pierre J. Issa, Gail J. Roboz, David A. Rizzieri et al. · The Lancet Oncology · 2015 · 281 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma et al. · Blood · 2020 · 210 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

Hagop M. Kantarjian, Gail J. Roboz, Patricia Kropf et al. · The Lancet Oncology · 2017 · 154 citations · Full text

Medicine, Hematology, Pharmacology +6

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths et al. · The Lancet Haematology · 2023 · 85 citations

Medicine, Pharmacokinetics, Pharmacology +13

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

Gail J. Roboz, Hagop M. Kantarjian, Karen Yee et al. · Cancer · 2017 · 66 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13